291 related articles for article (PubMed ID: 18622372)
1. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants.
Montgomery SA
CNS Spectr; 2008 Jul; 13(7 Suppl 11):27-33. PubMed ID: 18622372
[TBL] [Abstract][Full Text] [Related]
2. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
Stahl SM; Grady MM; Moret C; Briley M
CNS Spectr; 2005 Sep; 10(9):732-47. PubMed ID: 16142213
[TBL] [Abstract][Full Text] [Related]
3. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
4. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
[TBL] [Abstract][Full Text] [Related]
5. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
[TBL] [Abstract][Full Text] [Related]
6. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
7. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
Ishigooka J
Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
[TBL] [Abstract][Full Text] [Related]
8. The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability.
Cosci F; Chouinard G; Chouinard VA; Fava GA
Riv Psichiatr; 2018; 53(2):95-99. PubMed ID: 29674777
[TBL] [Abstract][Full Text] [Related]
9. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Lee SI; Keltner NL
Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
[No Abstract] [Full Text] [Related]
10. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
Jones CK; Eastwood BJ; Need AB; Shannon HE
Neuropharmacology; 2006 Dec; 51(7-8):1172-80. PubMed ID: 17045620
[TBL] [Abstract][Full Text] [Related]
11. Milnacipran: a unique antidepressant?
Kasper S; Pail G
Neuropsychiatr Dis Treat; 2010 Sep; 6(Suppl I):23-31. PubMed ID: 20856597
[TBL] [Abstract][Full Text] [Related]
12. Milnacipran and selective serotonin reuptake inhibitors in major depression.
Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
Peniston JH; Hu X; Potts SL; Wieman MS; Turk DC
Postgrad Med; 2012 Mar; 124(2):114-22. PubMed ID: 22437221
[TBL] [Abstract][Full Text] [Related]
14. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
15. [Side effects and its countermeasures of antidepressant].
Ueda N; Nakamura J
Nihon Rinsho; 2001 Aug; 59(8):1535-8. PubMed ID: 11519154
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
17. Managing depression and the appropriate use of SSRIs and SNRIs in primary care.
Nakao M
Intern Med; 2009; 48(18):1575-6. PubMed ID: 19755757
[No Abstract] [Full Text] [Related]
18. Use of serotonin norepinephrine reuptake inhibitors in the treatment of attention-deficit hyperactivity disorder in pediatrics.
Park P; Caballero J; Omidian H
Ann Pharmacother; 2014 Jan; 48(1):86-92. PubMed ID: 24259607
[TBL] [Abstract][Full Text] [Related]
19. New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs.
Mandrioli R; Protti M; Mercolini L
Curr Med Chem; 2018; 25(7):772-792. PubMed ID: 28707591
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
Schatzberg AF
J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
